MARKET

ACTU

ACTU

Actuate Therapeutics Inc
NASDAQ
8.00
-0.23
-2.79%
After Hours: 8.00 0 0.00% 16:00 04/17 EDT
OPEN
8.07
PREV CLOSE
8.23
HIGH
8.23
LOW
7.92
VOLUME
51.96K
TURNOVER
--
52 WEEK HIGH
11.73
52 WEEK LOW
5.51
MARKET CAP
156.25M
P/E (TTM)
-5.7266
1D
5D
1M
3M
1Y
5Y
1D
Actuate to Present Promising Data on Elraglusib in Advanced Salivary Gland Carcinoma at the AACR Annual Meeting 2025
Barchart · 3d ago
Weekly Report: what happened at ACTU last week (0407-0411)?
Weekly Report · 6d ago
Weekly Report: what happened at ACTU last week (0331-0404)?
Weekly Report · 04/07 12:32
Weekly Report: what happened at ACTU last week (0324-0328)?
Weekly Report · 03/31 12:50
Actuate Therapeutics files to sell 3.9M shares of common stock for holders
TipRanks · 03/28 10:31
ACTUATE THERAPEUTICS FILES PROSPECTUS TO OFFER, SALE OF UP TO 3.9 MLN SHARES BY B. RILEY PRINCIPAL CAPITAL II, LLC -SEC FILING
Reuters · 03/28 10:25
ACTUATE THERAPEUTICS INC - HAVE THE RIGHT TO SELL UP TO $50 MILLION NEWLY ISSUED SHARES - SEC FILING
Reuters · 03/28 10:06
ACTUATE THERAPEUTICS INC - ENTERS STOCK PURCHASE AGREEMENT WITH B. RILEY PRINCIPAL CAPITAL II, LLC - SEC FILING
Reuters · 03/28 10:06
More
About ACTU
Actuate Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). The Company is developing elraglusib, a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3b, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, which lead to tumor cell survival, growth, migration, and invasion. Its candidate products are Elraglusib Injection and Elraglusib Oral Tablet. Elraglusib is the lead drug in the portfolio and is being evaluated in a randomized Phase II trial in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC). Elraglusib is designed to act as a mediator of antitumor immunity through the inhibition of NF-kB and regulates multiple immune checkpoints and immune cell function.

Webull offers Actuate Therapeutics Inc stock information, including NASDAQ: ACTU real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ACTU stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ACTU stock methods without spending real money on the virtual paper trading platform.